Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitor-1 in cartilage-forming XXXX .

@entity1 @entity511 @entity3334 @entity1476 @entity5 @entity2843 @entity1495
The expression of @entity3334 and @entity2843 was studied in 10 benign cartilage-forming @entity5 (5 osteochondromas and 5 chondromas) and 39 @entity511 (14 central, 4 periosteal, 7 dedifferentiated, and 14 secondary @entity5 ). No expression of MMP and @entity2843 was detected in benign cartilage-forming @entity5 . In @entity511 , the expression of @entity3334 was detected in 84.6%, of @entity1476 in 71.8, of @entity1495 in 97.4, and of @entity2843 in 82.4% cases, the levels of expression of these markers varied from 10 to 60%. The expression of @entity3334 was not associated with @entity1 gender, maximum size and degree of differentiation of the @entity5 , but was linked with age. The expression of @entity3334 was more often detected in central and dedifferentiated @entity511 ; the expression of @entity3334 (+) was significantly associated with 3-year relapse-free and 5-year overall survival of the @entity1 . The expression of @entity3334 in the @entity5 was associated with unfavorable course of the disease. The values of @entity1476 expression in @entity511 did not reflect the main clinical morphological characteristics of the disease and its prognosis. The level of @entity1495 protein expression in @entity511 >= 40% is prognostically unfavorable, while <40% is a favorable factor for 3-year relapse-free survival. The risk of disease relapse within 1 year after the beginning of therapy was maximum in T3 @entity5 with expression of @entity1495 protein >= 40%. No relationships between the parameters of @entity2843 expression in @entity511 and the main clinical morphological characteristics of the disease and its prognosis were detected.
